Octreotide Injection

342 interactions 555 cited references

Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot

About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone

13 Contraindicated 325 Major 4 Moderate

All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Abemaciclib Verzenio Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Acalabrutinib Calquence Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Acarbose Prandase® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Acecainide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Acetophenazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Adagrasib Krazati An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Octreotide Injection Ajmaline An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Albiglutide An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Alfentanil Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Alogliptin Nesina An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Aluminum Carbonate, Basic Decreased octreotide bioavailability Details Octreotide Injection Aluminum Hydroxide AlternaGEL® Decreased octreotide bioavailability Details Octreotide Injection Aluminum Phosphate Decreased octreotide bioavailability Details Octreotide Injection Amiodarone Nexterone An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Amisulpride Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Octreotide Injection Amitriptyline Elavil An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Amoxapine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Anagrelide Agrylin Increased risk of QT interval prolongation Details Octreotide Injection Apomorphine Apokyn An increased risk of QT interval prolongation Details Octreotide Injection Aprindine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Aripiprazole Abilify An increased risk of QT interval prolongation Details Octreotide Injection Aripiprazole Lauroxil Aristada An increased risk of QT interval prolongation Details Octreotide Injection Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Artemether An increased risk of QT interval prolongation Details Octreotide Injection Asenapine Saphris Increased risk of QT interval prolongation Details Octreotide Injection Astemizole An increased risk of QT interval prolongation Details Octreotide Injection Atazanavir Reyataz An increased risk of QT interval prolongation Details Octreotide Injection Axitinib Inlyta Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Azimilide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Azithromycin AzaSite An increased risk of QT interval prolongation Details Octreotide Injection Bedaquiline Sirturo Increased risk of QT interval prolongation Details Octreotide Injection Bosutinib Bosulif Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Bretylium An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Brigatinib Alunbrig Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Buprenorphine Belbuca An increased risk of QT interval prolongation Details Octreotide Injection Calcium Carbonate Alka-Mints Decreased octreotide bioavailability Details Octreotide Injection Calcium Silicate Decreased octreotide bioavailability Details Octreotide Injection Canagliflozin Invokana An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Ceritinib Zykadia An increased risk of QT interval prolongation Details Octreotide Injection Chloral Hydrate An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.